Nuvalent/NUVL

$65.51

-3.66%
-
1D1W1MYTD1YMAX

About Nuvalent

Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. It is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, NVL-520, is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. LC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor.

Ticker

NUVL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

James Porter

Employees

92

Headquarters

Cambridge, United States

Nuvalent Metrics

BasicAdvanced
$4.2B
Market cap
-
P/E ratio
-$2.16
EPS
-
Beta
-
Dividend rate
$4.2B
$89.39
$27.30
429.67K
22.829
-20.78%
-21.7%
-21.7%
5.991
5.991
-31.76%

What the Analysts think about Nuvalent

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 7 analysts.
55.92% upside
High $110.00
Low $95.00
$65.51
Current price
$102.14
Average price target

Nuvalent Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-38.2M
13.69%
Profit margin
0%
-

Nuvalent Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 3.18%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.44
-$0.51
-$0.59
-$0.62
-
Expected
-$0.51
-$0.53
-$0.58
-$0.60
-$0.67
Surprise
-14.1%
-3.15%
1.29%
3.18%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Nuvalent stock?

Nuvalent (NUVL) has a market cap of $4.2B as of April 14, 2024.

What is the P/E ratio for Nuvalent stock?

The price to earnings (P/E) ratio for Nuvalent (NUVL) stock is 0 as of April 14, 2024.

Does Nuvalent stock pay dividends?

No, Nuvalent (NUVL) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next Nuvalent dividend payment date?

Nuvalent (NUVL) stock does not pay dividends to its shareholders.

What is the beta indicator for Nuvalent?

Nuvalent (NUVL) does not currently have a Beta indicator.

What is the Nuvalent stock price target?

The target price for Nuvalent (NUVL) stock is $102.14, which is 55.92% above the current price of $65.51. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Nuvalent stock

Buy or sell Nuvalent stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing